Immutep (NASDAQ:IMMP) Given New $7.00 Price Target at Robert W. Baird

Immutep (NASDAQ:IMMP) had its price objective raised by equities research analysts at Robert W. Baird from $6.00 to $7.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s price objective indicates a potential upside of 234.93% from the stock’s previous close.

Immutep Stock Up 11.8 %

NASDAQ IMMP opened at $2.09 on Friday. Immutep has a 1 year low of $1.58 and a 1 year high of $3.34. The stock’s fifty day moving average price is $2.12 and its 200 day moving average price is $2.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 18.25 and a quick ratio of 18.25.

Institutional Trading of Immutep

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new stake in shares of Immutep during the 2nd quarter valued at about $26,000. BNP Paribas Financial Markets boosted its stake in Immutep by 15.4% during the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock worth $82,000 after purchasing an additional 4,700 shares during the last quarter. Virtu Financial LLC grew its holdings in shares of Immutep by 269.4% during the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock worth $105,000 after buying an additional 32,864 shares in the last quarter. XY Capital Ltd acquired a new stake in shares of Immutep in the second quarter valued at about $105,000. Finally, Meridian Wealth Management LLC lifted its stake in shares of Immutep by 4.5% in the third quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock worth $881,000 after buying an additional 17,250 shares in the last quarter. Institutional investors and hedge funds own 2.32% of the company’s stock.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.